Home
About Us
About Us
Board of Directors
Scientific Advisory Board
Management Team
Careers
For Researchers
Paxalisib
EVT801
Collaborating with Kazia
Publications and Presentations
For Partners
Our Current Partners
What We Are Looking For
For Patients
Accessing Kazia Drug Candidates in Clinical Trials
Accessing Kazia Drug Candidates for Compassionate Use
Resources for Patients
For Investors
Press Releases
ASX Announcements
Delisting from ASX
How to convert unlisted shares to ADSs
SEC Filings
Corporate Presentations
Annual Reports
Financial Reports
AGM
Corporate Governance
Shareholder Services
Media Centre
Overview
Video
Coverage
Contact
Contact Us
Subscribe to email alerts
Heading &
Sub-heading can be edited through HQI
Home
>
For Investors
>
ASX Announcements
Press Releases
ASX Announcements
Delisting from ASX
How to convert unlisted shares to ADSs
SEC Filings
Corporate Presentations
Annual Reports
Financial Reports
AGM
Corporate Governance
Shareholder Services
ASX Announcements
Filter by Year:
2023
2022
2021
2020
2019
2018
11-May-2018
Kazia Shareholder Newsletter
29-Mar-2018
Kazia commences Phase II clinical study of GDC-0084
19-Mar-2018
Kazia presentation to Proactive Investors CEO series
7-Mar-2018
Notice of change in interests of substantial holder
6-Mar-2018
Kazia responds to share trading on ASX and Nasdaq
23-Feb-2018
Kazia receives FDA orphan drug designation for GDC 0084
21-Feb-2018
Kazia Appendix 4D, Half yearly accounts and Chairmans letter
19-Feb-2018
Kazia change of address
19-Feb-2018
Kazia receives $4m R&D tax rebate
5-Feb-2018
Kazia Appendix 3B
Previous
1
2
3
4
5
6
Next
